NCT02710708 - YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China | Biotech Hunter

Enrollment

1,921

Participants

Timeline

Start Date

May 27, 2016

Primary Completion Date

July 3, 2018

Study Completion Date

July 3, 2018

Conditions

Contraception

Interventions

DRUG

EE20/DRSP (YAZ, BAY86-5300)

YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets

Trial Locations (38)

100026

Beijing

100029

Beijing

100034

Beijing

100038

Beijing

100123

Beijing

100191

Beijing

100853

Beijing

200040

Shanghai

200127

Shanghai

210006

Nanjing

210008

Nanjing

213003

Changzhou

214002

Wuxi

261031

Weifang

300052

Tianjin

310006

Hangzhou

310016

Hangzhou

325000

Wenzhou

330006

Nanchang

414000

Yueyang

430014

Wuhan

510405

Guangzhou

510623

Guangzhou

518036

Shenzhen

530021

Nanning

545006

Liuzhou

610091

Chengdu

650011

Kunming

650032

Kunming

710061

Xi'an

Unknown

Xiamen

Changshacun

Weifang

Zibo

Ürümqi

Hangzhou

050035

Shijiazhuang

030001

Taiyuan